Literature DB >> 11378002

More 'malignant' than cancer? Five-year survival following a first admission for heart failure.

S Stewart1, K MacIntyre, D J Hole, S Capewell, J J McMurray.   

Abstract

BACKGROUND: The prognostic impact of heart failure relative to that of 'high-profile' disease states such as cancer, within the whole population, is unknown.
METHODS: All patients with a first admission to any Scottish hospital in 1991 for heart failure, myocardial infarction or the four most common types of cancer specific to men and women were identified. Five-year survival rates and associated loss of expected life-years were then compared.
RESULTS: In 1991, 16224 men had an initial hospitalisation for heart failure (n=3241), myocardial infarction (n=6932) or cancer of the lung, large bowel, prostate or bladder (n=6051). Similarly, 14842 women were admitted for heart failure (n=3606), myocardial infarction (n=4916), or cancer of the breast, lung, large bowel or ovary (n=6320). With the exception of lung cancer, heart failure was associated with the poorest 5-year survival rate (approximately 25% for both sexes). On an adjusted basis, heart failure was associated with worse long-term survival than bowel cancer in men (adjusted odds ratio, 0.89; 95% CI, 0.82-0.97; P<0.01) and breast cancer in women (odds ratio, 0.59; 95% CI, 0.55-0.64; P<0.001). The overall population rate of expected life-years lost due to heart failure in men was 6.7 years/1000 and for women 5.1 years/1000.
CONCLUSION: With the notable exception of lung cancer, heart failure is as 'malignant' as many common types of cancer and is associated with a comparable number of expected life-years lost.

Entities:  

Mesh:

Year:  2001        PMID: 11378002     DOI: 10.1016/s1388-9842(00)00141-0

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  222 in total

1.  Adipose tissue-derived stem cells display a proangiogenic phenotype on 3D scaffolds.

Authors:  Evgenios A Neofytou; Edwin Chang; Bhagat Patlola; Lydia-Marie Joubert; Jayakumar Rajadas; Sanjiv S Gambhir; Zhen Cheng; Robert C Robbins; Ramin E Beygui
Journal:  J Biomed Mater Res A       Date:  2011-05-31       Impact factor: 4.396

2.  Palliative care for heart failure.

Authors:  Simon Stewart; John J V McMurray
Journal:  BMJ       Date:  2002-10-26

Review 3.  Contemporary management of heart failure in clinical practice.

Authors:  J G F Cleland
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

4.  Clinical burden and health service challenges of chronic heart failure.

Authors:  F D Richard Hobbs
Journal:  Br J Gen Pract       Date:  2010-08       Impact factor: 5.386

Review 5.  Soluble guanylate cyclase modulators in heart failure.

Authors:  Veselin Mitrovic; Ana Jovanovic; Stefan Lehinant
Journal:  Curr Heart Fail Rep       Date:  2011-03

6.  [Diminishing borders between cardiology and cardiothoracic surgery: quo vadis?].

Authors:  T Schilling; R Bekeredjian; A Haverich; H A Katus
Journal:  Chirurg       Date:  2010-12       Impact factor: 0.955

7.  Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure.

Authors:  S Szmit; M Jank; H Maciejewski; M Grabowski; R Glowczynska; A Majewska; K J Filipiak; T Motyl; G Opolski
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

Review 8.  The potential role of endogenous bacteriophages in controlling invading pathogens.

Authors:  Andrzej Górski; Beata Weber-Dabrowska
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

9.  Survival differences between heart failure in general practices and in hospitals.

Authors:  O Wendelboe Nielsen; J Hilden; T McDonagh; J Fischer Hansen
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

10.  Linoleate-rich high-fat diet decreases mortality in hypertensive heart failure rats compared with lard and low-fat diets.

Authors:  Adam J Chicco; Genevieve C Sparagna; Sylvia A McCune; Christopher A Johnson; Robert C Murphy; David A Bolden; Meredith L Rees; Ryan T Gardner; Russell L Moore
Journal:  Hypertension       Date:  2008-07-28       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.